A Call for More Voices on Hormone Optimization, Quality, Safety, & Efficacy
Originally developed in 1939 for women who underwent radical hysterectomies—and widely used in Europe and Australia—compounded bio-identical hormone pellet therapy is the longest studied form of hormone replacement therapy to date.
But more study is needed to build confidence within the scientific community and to increase access, as appropriate, to a broader continuum of safe, effective treatment options.
BioTE® seeks to be a leading industry voice for hormone optimization quality, safety, efficacy and access. Human hormones are inherently idiosyncratic, which means that patients need personalized, compounded solutions that offer more flexibility than other forms of hormone therapy can offer. We are calling for more clinical research in the poorly-understood field of hormone therapy, and working to produce our own contributions to this field by sharing our experiences with over 2 million pellet insertions.
Recognizing that a gap remains to be filled in formal clinical research, BioTE® is also gathering experiential insights to inform the direction such clinical research might take in the effort to confirm with science that which patient experience is showing us. See here for patients’ experiences in their own words.
BioTE® is the ONLY hormone optimization company dedicated to clinical research
Breast cancer study
- 9-year retrospective review
- To demonstrate testosterone is breast protective, particularly when delivered - by subcutaneous pellet therapy
Testosterone and/or Testosterone/ Estradiol delivered subcutaneously as a pellet implant significantly reduced the incidence of breast cancer in pre- and - post-menopausal women
- Review of 7 years of data - from 2012-2019
- To identify adverse events for males and females who underwent subcutaneous pellet therapy. The overall complication rate was < 1%
- Currently underway
- Year-long study with - 60 participating clinics - and 1000+ patients
- To objectively measure the positive beneficial effects of testosterone subcutaneous hormone therapy in both pre- and post-menopausal women and hypo-gonadal men